TY - JOUR
T1 - Erratum to
T2 - First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors (Invest New Drugs 10.1007/s10637-017-0438-z)
AU - Fu, S.
AU - Hirte, H.
AU - Welch, S.
AU - Ilenchuk, T. T.
AU - Lutes, T.
AU - Rice, C.
AU - Fields, N.
AU - Nemet, A.
AU - Dugourd, D.
AU - Piha-Paul, S.
AU - Subbiah, V.
AU - Liu, L.
AU - Gong, J.
AU - Hong, D.
AU - Stewart, J. M.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - The article First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors, written by S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, and J. M. Stewart, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 01 February 2017 without open access.
AB - The article First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors, written by S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, and J. M. Stewart, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 01 February 2017 without open access.
UR - http://www.scopus.com/inward/record.url?scp=85017151970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017151970&partnerID=8YFLogxK
U2 - 10.1007/s10637-017-0455-y
DO - 10.1007/s10637-017-0455-y
M3 - Comment/debate
C2 - 28389981
AN - SCOPUS:85017151970
SN - 0167-6997
VL - 35
SP - 397
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -